Leerink Partners Downgrades Zentalis Pharmaceuticals (ZNTL) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Price: $2.32 -3.33%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Join SI Premium – FREE
Leerink Partners analyst Andrew Berens downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Outperform to Market Perform with a price target of $15.00 (from $37.00).
For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.
Shares of Zentalis Pharmaceuticals closed at $12.48 yesterday.
You May Also Be Interested In
- JD.com, Inc (JD) PT Lowered to $33 at US Tiger Securities
- Kotak Downgrades Lenskart Solutions (LENSKART:IN) to Reduce (3)
- CrowdStrike (CRWD) PT Raised to $320 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
